Vaccine contract manufacturing involves an arrangement where outside producers are engaged to create vaccines, overseeing the production, packing, and labeling of vaccines based on the specifications and demands of the contracting business or organization. The primary benefit of vaccine contract manufacturing is the simplification of production, resulting in cost savings and fewer operational challenges.
The main types of services involved in vaccine contract manufacturing include fill-finish and bulk products. Fill-finish specifically pertains to the filling and finishing stages of the vaccine manufacturing process. In the pharmaceutical industry, finishing involves the sterilization and standardization of vaccine components into containers, while filling refers to adding them to containers and sealing them properly. The vaccines produced through this process include inactivated vaccines, live-attenuated vaccines, RNA (ribonucleic acid) vaccines, subunit vaccines, and toxoid-based vaccines. These vaccines are prepared through downstream and upstream processes on preclinical, clinical, and commercial scales of operation, catering to both human use and veterinary end-users.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The vaccine contract manufacturing research report is one of a series of new reports from The Business Research Company that provides vaccine contract manufacturing market statistics, including the vaccine contract manufacturing industry's global market size, regional shares, competitors with vaccine contract manufacturing market share, detailed vaccine contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine contract manufacturing industry. This vaccine contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vaccine contract manufacturing market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.88 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to traditional vaccine manufacturing limitations, global disease outbreaks driving vaccine demand, regulatory support for contract manufacturing, increasing complexity of vaccine production, and surge in vaccine research and development.
The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $5.78 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to growing emphasis on pandemic preparedness, increased outsourcing in pharmaceutical manufacturing, expansion of biopharmaceutical companies, accelerated vaccine development timelines, global initiatives for vaccine accessibility. Major trends in the forecast period include integration of single-use technologies in manufacturing, rise in personalized medicine approaches to vaccine development, development of mRNA and viral vector vaccines, adoption of continuous manufacturing processes, expansion of fill-finish services.
The forecast of 10.4% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. vaccine production by increasing costs for single-use bioreactors and adjuvant raw materials imported from China and India, potentially delaying pandemic preparedness and raising public health program expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in initiatives promoting vaccinations is set to drive the growth of the vaccine contract manufacturing market in the future. Vaccination serves as an easy, safe, and effective method to defend against contagious diseases by enhancing the immune system and fortifying the body's defenses. The advancement and enhancement of various vaccine manufacturing processes to support vaccine contract manufacturing are expected with increasing initiatives favoring vaccinations. An illustrative example is the U.S. Department of Health and Human Services' announcement in November 2022 of a new $350 million initiative for HRSA (Health Resources and Services Administration)-supported health facilities to enhance COVID-19 vaccine availability, particularly for marginalized communities. Thus, the surge in initiatives supporting vaccinations is a catalyst for the growth of the vaccine contract manufacturing market.
The increasing prevalence of infectious diseases globally is expected to drive the growth of the vaccine contract manufacturing market. Infectious diseases are disorders caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When outbreaks of infectious diseases occur, such as influenza, measles, or emerging viruses, there is an urgent demand for vaccines to prevent further spread. Contract manufacturers can rapidly scale up production to meet these urgent needs. For instance, in December 2022, data from the Office for National Statistics, a UK-based national statistics institute, indicated that infection rates rose among individuals aged 35 to 69 and also increased for those in school years 12 to 24. The total hospital admission rate for confirmed COVID-19 patients in England rose to 9.56 per 100,000 individuals, with ICU and high dependency unit admissions increasing to 0.29 per 100,000 inhabitants. Additionally, in August 2024, the UK Health Security Agency reported 368 measles cases in England for 2023, nearly a sevenfold increase from the 53 cases in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Therefore, the rise in infectious diseases worldwide is driving the growth of the vaccine contract manufacturing market.
Strategic partnerships are a prominent trend gaining traction in the vaccine contract manufacturing market. Major companies are collaborating with entities in this sector to strengthen their market positions. For example, in January 2023, Vaxxas, an Australia-based biotechnology firm known for its innovative needle-free vaccination technology, joined forces with the Coalition for Epidemic Preparedness Innovations, a Norway-based foundation, to finance and coordinate the development of new vaccines and advance Vaxxas' needle-free vaccine patch delivery technology. This initiative aims to eliminate the need for frozen storage for mRNA vaccines. Additionally, in October 2024, LenioBio, a Germany-based biotech company, partnered with ReciBioPharm, a US-based contract development and manufacturing organization (CDMO), to enhance its protein manufacturing capabilities and expedite vaccine production. This partnership supports LenioBio's strategy to broaden the scope of its CEPI-funded project, which seeks to showcase the speed and efficiency of its proprietary ALiCE protein expression technology in producing vaccine-related proteins for clinical trials.
Major companies in the vaccine contract manufacturing market are directing their efforts toward establishing production sites dedicated to vaccine contract manufacturing. This entails creating facilities exclusively for the manufacturing and production of vaccines on a contractual basis. WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO), expanded its capabilities with the opening of its first standalone vaccine CDMO site in Suzhou, China, in September 2023. This expansion enhances WuXi Vaccines' capacity to contribute to vaccine development and manufacturing, reinforcing its pivotal role in advancing global healthcare solutions.
In October 2024, SK bioscience, a South Korea-based vaccine and biotech firm, acquired a controlling stake in IDT Biologika for approximately $244 million. This acquisition is part of SK bioscience's strategy to accelerate growth, with a goal of achieving consolidated sales of KRW 1 trillion (around USD 757.6 million) within the next five years. The company also intends to expand further by launching next-generation pneumococcal vaccines, positioning itself for continued financial growth beyond 2028. IDT Biologika is a German-based company that operates as a vaccine contract development and manufacturing organization (CDMO).
Major companies operating in the vaccine contract manufacturing market include Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon plc, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L
North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the vaccine contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vaccine contract manufacturing market consists of revenues earned by entities by providing services such as analytical, quality control studies, cell or virus banking, and cold chain services. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine contract manufacturing market also includes sales of synthetic vaccines and DNA (deoxyribonucleic acid) vaccines, which are used in providing vaccine contract manufacturing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vaccine Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vaccine contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vaccine contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vaccine contract manufacturing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Service Type: Fill-Finish; Bulk Product
- 2) By Vaccine Type: Inactivated Vaccines; Live-Attenuated Vaccines; RNA (Ribonucleic Acid) Vaccines; Subunit Vaccines; Toxoid-Based Vaccines
- 3) By Process: Downstream; Upstream
- 4) By Scale Of Operation: Preclinical; Clinical; Commercial
- 5) By End-Use: Human Use; Veterinary
- Subsegments:
- 1) By Fill-Finish: Aseptic Fill-Finish; Lyophilization; Vial Filling; Syringe Filling
- 2) By Bulk Product: Cell Culture; Microbial Fermentation; Antigen Production; Buffer Preparation
- Companies Mentioned: Pfizer Inc; Johnson & Johnson; AbbVie Inc.; Sanofi; GlaxoSmithKline; Merck KGaA; Fujifilm Holdings Corporation; Moderna; BioNTech; GSK Vaccines; AstraZeneca PLC; Ajinomoto Co. Inc.; Icon plc; Lonza Group AG; Cytiva; Catalent Inc.; Charles River Laboratories International Inc.; Serum Institute of India Pvt. Ltd; Samsung Biologics; WuXi Biologics; Novavax; Sinovac Biotech; Emergent BioSolutions Inc.; Albany Molecular Research Inc.; Soligenix Inc.; Bio Farma; Curia Global Inc.; Hualan Biological Engineering; BioMARC; Bavarian Nordic A/S; AGC Biologics; IDT Biologika GmbH; Bharat Biotech; Goodwin Biotechnology Inc.; Biofabri S.L
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vaccine Contract Manufacturing Market Characteristics
3. Vaccine Contract Manufacturing Market Trends And Strategies
4. Vaccine Contract Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Vaccine Contract Manufacturing Growth Analysis And Strategic Analysis Framework
- 5.1. Global Vaccine Contract Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Vaccine Contract Manufacturing Market Growth Rate Analysis
- 5.4. Global Vaccine Contract Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Vaccine Contract Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Vaccine Contract Manufacturing Total Addressable Market (TAM)
6. Vaccine Contract Manufacturing Market Segmentation
- 6.1. Global Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fill-Finish
- Bulk Product
- 6.2. Global Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Inactivated Vaccines
- Live-Attenuated Vaccines
- RNA (Ribonucleic Acid) Vaccines
- Subunit Vaccines
- Toxoid-Based Vaccines
- 6.3. Global Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Downstream
- Upstream
- 6.4. Global Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Preclinical
- Clinical
- Commercial
- 6.5. Global Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Human Use
- Veterinary
- 6.6. Global Vaccine Contract Manufacturing Market, Sub-Segmentation Of Fill-Finish, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Aseptic Fill-Finish
- Lyophilization
- Vial Filling
- Syringe Filling
- 6.7. Global Vaccine Contract Manufacturing Market, Sub-Segmentation Of Bulk Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cell Culture
- Microbial Fermentation
- Antigen Production
- Buffer Preparation
7. Vaccine Contract Manufacturing Market Regional And Country Analysis
- 7.1. Global Vaccine Contract Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Vaccine Contract Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Vaccine Contract Manufacturing Market
- 8.1. Asia-Pacific Vaccine Contract Manufacturing Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Vaccine Contract Manufacturing Market
- 9.1. China Vaccine Contract Manufacturing Market Overview
- 9.2. China Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Vaccine Contract Manufacturing Market
- 10.1. India Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Vaccine Contract Manufacturing Market
- 11.1. Japan Vaccine Contract Manufacturing Market Overview
- 11.2. Japan Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Vaccine Contract Manufacturing Market
- 12.1. Australia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Vaccine Contract Manufacturing Market
- 13.1. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Vaccine Contract Manufacturing Market
- 14.1. South Korea Vaccine Contract Manufacturing Market Overview
- 14.2. South Korea Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Vaccine Contract Manufacturing Market
- 15.1. Western Europe Vaccine Contract Manufacturing Market Overview
- 15.2. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Vaccine Contract Manufacturing Market
- 16.1. UK Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Vaccine Contract Manufacturing Market
- 17.1. Germany Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Vaccine Contract Manufacturing Market
- 18.1. France Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Vaccine Contract Manufacturing Market
- 19.1. Italy Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Vaccine Contract Manufacturing Market
- 20.1. Spain Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Vaccine Contract Manufacturing Market
- 21.1. Eastern Europe Vaccine Contract Manufacturing Market Overview
- 21.2. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Vaccine Contract Manufacturing Market
- 22.1. Russia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Vaccine Contract Manufacturing Market
- 23.1. North America Vaccine Contract Manufacturing Market Overview
- 23.2. North America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Vaccine Contract Manufacturing Market
- 24.1. USA Vaccine Contract Manufacturing Market Overview
- 24.2. USA Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Vaccine Contract Manufacturing Market
- 25.1. Canada Vaccine Contract Manufacturing Market Overview
- 25.2. Canada Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Vaccine Contract Manufacturing Market
- 26.1. South America Vaccine Contract Manufacturing Market Overview
- 26.2. South America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Vaccine Contract Manufacturing Market
- 27.1. Brazil Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Vaccine Contract Manufacturing Market
- 28.1. Middle East Vaccine Contract Manufacturing Market Overview
- 28.2. Middle East Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Vaccine Contract Manufacturing Market
- 29.1. Africa Vaccine Contract Manufacturing Market Overview
- 29.2. Africa Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Vaccine Contract Manufacturing Market Competitive Landscape And Company Profiles
- 30.1. Vaccine Contract Manufacturing Market Competitive Landscape
- 30.2. Vaccine Contract Manufacturing Market Company Profiles
- 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis
31. Vaccine Contract Manufacturing Market Other Major And Innovative Companies
- 31.1. Merck KGaA
- 31.2. Fujifilm Holdings Corporation
- 31.3. Moderna
- 31.4. BioNTech
- 31.5. GSK Vaccines
- 31.6. AstraZeneca PLC
- 31.7. Ajinomoto Co. Inc.
- 31.8. Icon plc
- 31.9. Lonza Group AG
- 31.10. Cytiva
- 31.11. Catalent Inc.
- 31.12. Charles River Laboratories International Inc.
- 31.13. Serum Institute of India Pvt. Ltd
- 31.14. Samsung Biologics
- 31.15. WuXi Biologics
32. Global Vaccine Contract Manufacturing Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Vaccine Contract Manufacturing Market
34. Recent Developments In The Vaccine Contract Manufacturing Market
35. Vaccine Contract Manufacturing Market High Potential Countries, Segments and Strategies
- 35.1 Vaccine Contract Manufacturing Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Vaccine Contract Manufacturing Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Vaccine Contract Manufacturing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
